Institutional shares held 19 Million
9.5K calls
8.1K puts
Total value of holdings $2.08B
$1.04M calls
$886K puts
Market Cap $1.85B
16,882,800 Shares Out.
Institutional ownership 112.67%
# of Institutions 280


Latest Institutional Activity in LGND

Top Purchases

Q1 2025
Jacobs Levy Equity Management, Inc Shares Held: 157K ($17.2M)
Q1 2025
Ranger Investment Management, L.P. Shares Held: 190K ($20.8M)
Q1 2025
Center Book Partners LP Shares Held: 68.3K ($7.48M)
Q1 2025
Nuveen, LLC Shares Held: 44.3K ($4.85M)
Q1 2025
Russell Investments Group, Ltd. Shares Held: 135K ($14.8M)

Top Sells

Q1 2025
Baird Financial Group, Inc. Shares Held: 11.6K ($1.27M)
Q1 2025
Prudential Financial Inc Shares Held: 41K ($4.48M)
Q1 2025
Gamma Investing LLC Shares Held: 593 ($64.9K)
Q1 2025
Envestnet Asset Management Inc Shares Held: 26.6K ($2.91M)
Q1 2025
Vanguard Group Inc Shares Held: 2.06M ($225M)

About LGND

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; and Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company's partners and licenses programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver and kidney disease, and other diseases. Further, it sells Captisol materials. The company was incorporated in 1987 and is headquartered in Emeryville, California.


Insider Transactions at LGND

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
138K Shares
From 22 Insiders
Other acquisition or disposition 1.3K shares
Exercise of conversion of derivative security 33.5K shares
Grant, award, or other acquisition 89.7K shares
Open market or private purchase 13.5K shares
Sell / Disposition
105K Shares
From 9 Insiders
Payment of exercise price or tax liability 35.7K shares
Open market or private sale 68.9K shares

Track Institutional and Insider Activities on LGND

Follow LIGAND PHARMACEUTICALS INC and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells LGND shares.

Notify only if

Insider Trading

Get notified when an Ligand Pharmaceuticals Inc insider buys or sells LGND shares.

Notify only if

News

Receive news related to LIGAND PHARMACEUTICALS INC

Track Activities on LGND